A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.

NCT07301866 | Recruiting Phase 1 DMC

• 1 other identifier: ECT-001-CB-013
• Study Type: interventional
• Target: 7
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical study is testing a new way to improve stem cell transplants for adults with high-risk blood cancers, such as leukemia or myelodysplasia, who do not have a suitable donor. The transplant uses stem cells from umbilical cord blood that have been expanded in the lab using a molecule called UM171. Previous studies showed that UM171 helps these cells grow and work better, leading to faster blood count recovery and fewer complications. In this study, researchers are testing whether increasing the dose of UM171 during the lab expansion process can make the transplant less toxic. The hypothesis is that using a higher dose of UM171 to expand cord blood stem cells will help patients recover blood counts faster after transplant by improving the growth and function of the cells. This may lead to better immune recovery, fewer infections, shorter hospital stays, and improved overall outcomes. Only seven patients will be enrolled, and they will be followed for one year after their transplant.

Conditions

Acute Leukemia, High Risk; Myelodysplastic Syndromes, High Risk; Hematologic Malignancy Requiring an Allogeneic Hematopoietic Stem Cell Transplant Lacking a Donor

Keywords

High risk hematologic malignancy; Cord blood transplant; UM171; ECT-001-CB; Lack of donor for stem cell transplant donor; Acute leukemia; Myelodysplastic syndrome

Outcome Measures

Primary Outcomes (3)

• Incidence of grade 3 or higher adverse events (AEs)

  Incidence of grade 3 or higher adverse events (AEs)

  From the start of pre-transplant conditioning of first patient throught 1 year post-transplant of last patient

• Feasibility of manufacturing and infusion

  Proportion of selected grafts that will be expanded and meet release criteria and be successfully infused to the patient

  From first day of product manufacturing for the first patient throught the infusion of the product to the last patient, up to Month 13.

• Time to neutrophil engraftment

  Neutrophil engraftment is defined as the first day of neutrophil count (ANC) ≥ 0.5 x 109/L for 3 consecutive days; first day of ANC ≥ 0.1 x 109/L will also be documented.

  From day of transplant (Day 0) throught day of neutrophil engraftment, up to Day 42 post-transplant.

Secondary Outcomes (8)

• Incidence of NRM at 1 year post transplant

  From day of transplant (Day 0) of first patient throught 1 year post-transplant of last patient

• Time to platelet engraftment

  From day of transplant (Day 0) throught day of platelet engraftment, up to Day 42 post-transplant.

• Incidence of graft failure

  From day of transplant (Day 0) of first patient throught 1 year post-transplant of last patient

• Progression-free survival (PFS) at 1 year post-transplant

  From day of transplant (Day 0) of first patient throught 1 year post-transplant of last patient

• Overall Survival (OS) at 1 year post-transplant

  From day of transplant (Day 0) of first patient throught 1 year post-transplant of last patient

Study Arms (1)

UM171 CB transplant (ECT-001-CB) with optimized dose of UM171

EXPERIMENTAL

Biological: ECT-001-CB

Interventions

ECT-001-CB BIOLOGICAL

UM171-expanded cord blood

UM171 CB transplant (ECT-001-CB) with optimized dose of UM171

Eligibility Criteria

• Age: 18 Years - 67 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects ≥ 18 and ≤ 67 years old,
• Patient with either i. High risk acute leukemia or myelodysplasia defined as expected 2 year OS or PFS \< 40% after a conventional allogeneic HSC transplant or ii. A hematologic malignancy requiring an allogeneic hematopoietic stem cell transplant and lack of a suitable HLA identical, haploidentical or 7/8 HLA matched donor.
• Availability of an adequate CB for expansion:
• i. ≥ 5/8 HLA match when A, B, C and DRB1 are performed at the allele level.
• ii. Minimal cell dose: TNC ≥ 1.5 x 107/kg, and CD34 ≥ 0.5 x 105/kg. iii. Needs to be erythrodepleted by bank prior to cryopreservation. iv. Must comply with local site regulations AND, come from a cord bank that is FACT, or AABB accredited, or FDA approved or eligible for NMDP IND (unless PI approves another bank).
• v. To meet eligibility criteria, the patient's weight at time of cord selection will be used; however, if this weight has increased by more than 5% at time of admission to hospital and with the new weight the patient no longer meets eligibility criteria for cell dose, LI approval will be required to move forward with the selected cord. Every attempt will be made to always use the most recent weight in cord selection
• Patients with adequate physical function as measured by:
• i. Karnofsky score ≥ 70% ii. Hematopoietic comorbidity index (HCT-CI): 0-3 for 2nd transplant and age 60-65 years, 0-5 if \<60 years old, and 0-2 if 66-67 years.
• iii. Adequate cardiac function: Left ventricular ejection fraction ≥ 40% within 60 days prior to start of conditioning regimen iv. Adequate pulmonary function: Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and diffusing capacity corrected for hemoglobin (DLCOc) ≥ 50% of predicted within 60 days prior to start of conditioning regimen.
• v. Adequate hepatic function: Bilirubin \< 2 x ULN unless felt to be related to Gilbert's disease or hemolysis; AST and ALT ≤ 2.5 x ULN (the PI may approve up to 3 times ULN) ; alkaline phosphatase ≤ 5 x ULN.
• vi. Adequate renal function: Estimated or measured creatinine clearance ≥ 60 ml/min/1.73m2.
• A back up graft must have been identified prior to initiation of conditioning regimen.
• Signed written informed consent.
• Female patients of childbearing potential must have a negative serum pregnancy test within 30 days of enrolment and within 30 days of starting of preparative regimen; patient must be willing to use an effective contraceptive method while enrolled in the study.

You may not qualify if:

• Allogeneic or autologous myeloablative transplant within last 6 months.
• Patients with inadequate physical function as measured by:
• i. Active, uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of either progression of clinical symptoms or radiologic findings or lack of evidence of response to therapy).
• ii. Presence of a malignancy other than the one for which the HSC transplant is being performed, with an expected survival estimated to be less than 75% at 5 years.
• iii. Seropositivity for HIV. iv. Hepatitis B or C infection with measurable viral load. Patients with hepatitis B or C infection regardless of viral load require clear documentation of absence of cirrhosis by either fibroscan or biopsy.
• v. Liver cirrhosis.
• Positive anti-donor HLA antibodies with MFI above 1500 against the selected CB (PI may approve an MFI up to 5000; if above 2500, desensitization is strongly recommended)
• Use of an investigational agent within 30 days (defined as a drug not approved by Health Canada or FDA regardless of indication) of start of chemotherapy unless documented approval obtained from Sponsor.
• Presence of ≥30% blasts in bone marrow or ≥ 0.5 x109/L blasts in circulating blood
• Active central nervous system involvement or chloroma \> 2 cm.

Sponsors & Collaborators

• Ciusss de L'Est de l'Île de Montréal: lead
• Stem Cell Network: collaborator

Study Sites (1)

Hôpital Maisonneuve-Rosemont

Montreal, Quebec, H1T 2M4, Canada

RECRUITING

MeSH Terms

Conditions

Myelodysplastic Syndromes

Condition Hierarchy (Ancestors)

Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Sandra Cohen, Dr.

  CIUSSS de l'Est-de-l'Ile-de-Montréal

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Sandra Cohen, Dr.

CONTACT

514-252-3404; sandra.cohen.med@ssss.gouv.qc.ca

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr.

Study Record Dates

• First Submitted: November 27, 2025
• First Posted: December 24, 2025
• Study Start: October 6, 2025
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): March 1, 2028
• Last Updated: December 24, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, CSR
• Time Frame: IPD will be available after the completion of the study and publication of primary results, estimated to be within 12 months following the final patient's last follow-up visi
• Access Criteria: A proposal that describes planned analyses must be submitted to the Principal Investigator, Dr. Sandra Cohen, and a data sharing agreement must be signed.

Locations

CA (1)